在肺腺癌的预后价值的发展基于阿诺基斯相关的基因和初步实验验证的初步实验验证
Wenwei Guo1,2, Guang Zhao1, Suping Liu3
1Department of Thoracic Surgery, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
The journal of gene medicine
|June 1, 2023
概括
与阿诺基斯相关的基因 (ARG) 可以预测肺腺癌 (LUAD) 的结果. 一个使用六个关键ARG的新模型有助于对患者进行分层,以提供量身定制的疗法,并改善LUAD中的生存预测.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 基因组学就是基因组学.
背景情况:
- 肺腺癌 (LUAD) 是一种具有高死亡率的侵袭性癌症.
- 阿诺基斯是一种编程细胞死亡形式,与瘤发育有关.
研究的目的:
- 为 LUAD.开发一种新的与阿诺基斯相关的基因 (ARG) 签名.
- 评估签名与临床特征,免疫透和药物敏感性的关联.
主要方法:
- 使用了癌症基因组图谱 (TCGA) 数据集.
- 基于使用Cox回归的与生存相关的ARG构建了一个风险模型.
- 进行了基因本体学,KEGG,估计和CIBERSORT分析.
- 在LUAD细胞系中验证了枢纽ARG表达.
主要成果:
- 确定了一个六个枢纽的ARG签名 (LDHA,SLC2A1,SERPINB5,ITGB4,BRCA2,PIK3R1).
- 该ARG签名准确地将LUAD患者分为低风险和高风险组.
- 预后风险评分是整体存活率的重要独立预测指标.
- 风险群体之间表现出不同的免疫特征和药物敏感性.
- 开发了一个整合风险评分和临床病理特征的名图.
- 在LUAD组织/细胞系中实验验验证了五个关键ARG的上调.
结论:
- 在LUAD中,ARG可以作为致癌因素.
- ARG签名是患者分层的一个有效工具.
- 该模型有助于定制LUAD疗法并预测存活率.
更多相关视频
09:08Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer
Published on: January 12, 2020
6.8K
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
7.3K
相关概念视频
02:07Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
01:21Cancer Survival Analysis
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...